NCT01723514View on ClinicalTrials.gov

Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

November 14, 2012

Primary Completion Date

July 10, 2014

Study Completion Date

July 10, 2014

Conditions

Migraine

Interventions

DRUG

Erenumab

Administered by subcutaneous injection once a month

DRUG

Placebo

Administered by subcutaneous injection once a month

Trial Locations (1)

3000

Research Site, Leuven

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY